Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada

被引：0
|
作者：
Fischer, A. [1 ]
Oppe, M. [2 ]
Stypa, S. [1 ]
Lukyanov, V. [3 ]
Petrakis, I. [4 ]
机构：
[1] Takeda Canada Inc, Patient Value & Access, Toronto, ON, Canada
[2] Axent Solut, Pharmacoecon, San Cristobal la Laguna, Spain
[3] IQVIA, Real World Insights, Amsterdam, Netherlands
[4] Takeda Inc, Payer Value & Patient Access, Boston, MA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P424
引用
收藏
页码：S387 / S387
页数：1
相关论文
共 50 条
  • [1] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Toruner, Murat
    Jonaitis, Laimas
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13): : 1215 - 1226
  • [2] Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
    Tribich, Samuel
    Maurice, James
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 173 - 173
  • [3] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Biemans, Vince B. C.
    Hoentjen, Frank
    Pierik, Marieke J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 92 - 92
  • [4] An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis
    Johnson, Amanda M.
    Loftus Jr, Edward V.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (12) : 1317 - 1327
  • [5] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis REPLY
    Sands, Bruce E.
    Schreiber, Stefan
    Lirio, Richard A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 93 - 94
  • [6] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
    Feagan, Brian G.
    Schreiber, Stefan
    Wolf, Douglas C.
    Axler, Jeffrey L.
    Kaviya, Arpeat
    James, Alexandra
    Curtis, Rebecca I.
    Geransar, Parnia
    Stallmach, Andreas
    Ehehalt, Robert
    Bokemeyer, Bernd
    Khalid, Javaria Mona
    O'Byrne, Sharon
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (06) : 1028 - 1035
  • [7] COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND
    Sruamsiri, R.
    VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [8] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [9] Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis
    Miyoshi, Jun
    Matsuura, Minoru
    Hisamatsu, Tadakazu
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (01) : 1 - 8
  • [10] Etrolizumab in moderate-to-severe ulcerative colitis
    Armuzzi, Alessandro
    Felice, Carla
    LANCET, 2014, 384 (9940): : 285 - 286
12345